SIA
JSPR icon

SkyView Investment Advisors’s Jasper Therapeutics JSPR Stock Holding History

SkyView Investment Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed – – 605
2022
Q1 		$0 Hold
1
– – ﹤0.01% 609
2021
Q4 		$0 Buy
+1
New +$94 ﹤0.01% 576

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

SkyView Investment Advisors's JSPR Position: Q2 2022 in Review

SkyView Investment Advisors sold out of Jasper Therapeutics (JSPR) in Q2 2022, closing a stake of 1 share.

SkyView Investment Advisors first reported a position in JSPR in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 23 funds tracked by Wall St. Rank hold JSPR as of Q2 2022.

  • SkyView Investment Advisors reported no remaining Jasper Therapeutics position as of Q2 2022 after selling out during the quarter.
  • SkyView Investment Advisors sold 1 Jasper Therapeutics share in Q2 2022.
  • SkyView Investment Advisors first reported a position in Jasper Therapeutics in Q4 2021 and held it in 2 quarters.
  • SkyView Investment Advisors's Jasper Therapeutics position peaked at $0 in Q1 2022.
  • 23 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2022.

Based on SkyView Investment Advisors's 13F filing for Q2 2022, filed 15 Nov 2022.